Table 1.
Baseline characteristics of the study population and study outcomes.
| Demographic characteristics | Total (n = 927) | IVT (n = 576) | MT (n = 351) | p |
|---|---|---|---|---|
| Age (years, median, IQR) | 68 (59–76) | 68 (59–76) | 69 (60–76) | 0.88 |
| Sex, male n (%) | 628 (68) | 379 (65) | 249 (71) | 0.08 |
| Hypertension, n (%) | 664 (72) | 417 (72) | 247 (70) | 0.59 |
| Diabetes mellitus, n (%) | 247 (30) | 173 (30) | 101 (29) | 0.72 |
| Hyperlipidemia, n (%) | 86 (9) | 47 (7) | 39 (11) | 0.2 |
| Atrial fibrillation, n (%) | 320 (35) | 164 (28) | 156 (44) | <0.001* |
| Current smoker, n (%) | 152 (16) | 145 (12) | 7 (6) | 0.067 |
| Stroke history, n (%) | 93 (10) | 38 (7) | 55 (16) | <0.001* |
| Admission NIHSS score, median (IQR) | 9 (4–14) | 5 (3–10) | 14 (11–19) | <0.001* |
| mRS 0–1 before stroke, n (%) | 859 (93) | 549 (95) | 310 (88) | <0.001* |
| Stroke onset to treat time, min, median (IQR) | 249 (196–307) | 173 (126–221) | 318 (278–352) | <0.001* |
| Stroke etiology (TOAST) n (%) | ||||
| Large-artery atherosclerosis | 557 (60) | 373 (65) | 184 (52) | <0.001* |
| Cardioembolism | 284 (31) | 128 (22) | 156 (44) | <0.001* |
| Other | 88 (9) | 77 (13) | 11 (3) | <0.001* |
| Anterior circulation, n (%) | 794 (86) | 497 (86) | 297 (85) | 0.56 |
| Day 1 NIHSS score, median (IQR) | 6 (2–13) | 3 (1–8) | 11 (7–21) | <0.001* |
| Hemorrhagic transformation, n (%) | 172 (19) | 67 (12) | 105 (30) | <0.001* |
| sICH, n (%) | 82 (9) | 43 (8) | 39 (11) | 0.05 |
| Functional outcome dependence (mRS>3), n (%) | 376 (410) | 143 (25) | 233 (66) | <0.001* |
| mRS score at 90 day, median (IQR) | 2 (0–4) | 1 (0–2) | 4 (1–5) | <0.001* |
| Mortality, n (%) | 116 (13) | 36 (6) | 80 (23) | <0.001* |
| Admission WBC, median (IQR) | 7.6 (6.0–9.7) | 7.2 (5.8–9.1) | 8.3 (6.4–10.7) | <0.001* |
| Admission neutrophils, median (IQR) | 5.0 (3.6–7.1) | 4.6 (3.5–6.4) | 5.9 (4.2–8.6) | <0.001* |
| Admission lymphocytes, median (IQR) | 1.6 (1.2–2.1) | 1.7 (1.3–2.2) | 1.5 (1.1–1.9) | <0.001* |
| Admission NLR, median (IQR) | 3.7 (1.7–6.8) | 2.6 (1.7–4.3) | 4.3 (2.5–6.8) | <0.001* |
| Day 1 WBC, median (IQR) | 8.3 (6.4–11.7) | 7.6 (6.4–9.6) | 9.6 (7.6–11.7) | <0.001* |
| Day 1 neutrophils, median (IQR) | 6.1 (4.8–8.1) | 5.4 (4.8–6.1) | 7.7 (7.1–8.1) | <0.001* |
| Day 1 lymphocytes, median (IQR) | 1.4 (1.0–2.1) | 1.5 (1.1–2.1) | 1.3 (1.0–1.8) | <0.001* |
| Day 1 NLR, median (IQR) | 4.3 (2.7–8.6) | 3.5 (2.7–5.6) | 5.9 (3.9–8.6) | <0.001* |
IVT, intravenous thrombolysis; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range; TOAST, trial of Org 10 172 in acute stroke treatment; WBC, while blood cell; sICH, symptomatic intracerebral hemorrhagic; NLR, neutrophil over lymphocytes ratio.
*
Statistically significant.